Please login to the form below

Not currently logged in
Email:
Password:

GSK comms head leaves to join AZ

GSK's vice-president for UK corporate affairs and EU communications is leaving to join AstraZeneca as global head of media relations

Neil McCrae, GlaxoSmithKline's (GSK) vice-president for UK corporate affairs and EU communications, is leaving to join AstraZeneca (AZ) as global head of media relations.

McCrae will leave at the beginning of 2008 after working for GSK for 11 years and will report to vice-president for group corporate communications, Caroline Hempstead. According to AZ, the position was created during the restructuring of the corporate affairs department at the company.

McCrae will be responsible for managing the group press office and building relationships with business and international media in London.

According to PR Week, McCrae's departure follows that of GSK's senior external communications manager, David Daley, who left to join The Health Protection Agency in the middle of November. Daley managed a team of five-strong team led by head of external communications Kate Hewer, who returned from maternity leave.

GSK has warned of job losses and has initiated cost-cutting measures to counter the falling sales experienced by its flagship diabetes drug, Avandia, as a result of cardiac safety warnings published in a US medical journal.

This week, GSK announced it would be shedding jobs from its US operations centre and a manufacturing site in North Carolina.

30th November 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...